Last update: Nov. 29, 2019
Increased level of risk
New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Very Low Risk, is now set to Low Risk.
Level of risk reviewed on Nov. 29, 2019
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
Inhibitor of platelet aggregation indicated in the prevention of post-operative thromboembolic complications associated with prosthetic heart valve.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic characteristics (moderately elevated molecular weight, high plasma protein binding and large volume of distribution), make it very unlikely its excretion into breast milk in significant amounts.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in cases of prematurity.
We do not have alternatives for Dipyridamole.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Instituto de Salud Infantil, Grecia-Institute of Child's Health in Greece
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM